Published Date: 08 Mar 2023
At a trial in Georgia on Wednesday, three drug traffickers won a case brought by the family of a drug addict, accusing the company of selling drugs.
Read Full NewsFormer UK prime minister Rishi Sunak has called for a targeted prostate cancer screening program for men most at high risk of the disease, reviving a national debate on how to save more lives and tackle health inequalities ...
In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly diagnosed ...
About half of women over 40 have dense breasts. The denser the breast tissue, the more difficult it is to spot cancer on a standard mammogram. Having dense breast tissue can make it harder to detect cancer and sometimes leads ...
Researchers from Rutgers Health and other institutions have discovered why a powerful leukemia drug eventually fails in most patients—and found a potential way to overcome that resistance.
1.
Researchers identify potential new therapeutic targets for treating T-cell lymphoma and natural killer cell tumors.
2.
Urinary tract cancer prediction models with high sensitivity and specificity
3.
Treatment of Oligometastatic EGFR-Mutant Lung Cancer
4.
In leukemia, allogeneic HCT is beneficial following primary induction failure.
5.
Updates from the 2022 WHO classification of kidney epithelial tumors
1.
Matrix Metalloproteinases in Stroke: Broad vs. Selective Inhibition Strategies
2.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
3.
Unraveling the Genetic Mystery of Hereditary Spherocytosis
4.
The Genetics of Bernard Soulier Syndrome: What We Know so Far
5.
The Converging Frontiers of Radiation Oncology and Systemic Therapies by 2025
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
2.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
4.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
5.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation